Merck revealed promising Phase 3 trial results for WINREVAIR, a new treatment aimed at pulmonary arterial hypertension (PAH). The HYPERION study involved about 320 global participants already ...

Long-term exposure to particulate matter in patients with pulmonary arterial hypertension increases risk for lung transplantation or death.

At 12 weeks, patients treated with ENV-101 showed statistically significant increases in lung volume compared with those ...

Panelists discuss how managing patients with comorbidities requires careful evaluation to distinguish true Group 1 PAH features from underlying cardiac or pulmonary disease, with a more measured ...

A cup and a half of leafy green vegetables could go a long way to addressing atherosclerotic vascular diseases (ASVD's), ...

Among patients with pulmonary arterial hypertension, once-daily treprostinil palmitil inhalation powder for 16 weeks reduced ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0 ...

In PAH, pulmonary rehabilitation referral and participation rates are low and are significantly affected by demographic and socioeconomic factors.

Increased eosinophil levels in COPD were associated with impaired abdominal aortic dynamics, highlighting a mechanistic link ...

BMPER attenuated PI3K/AKT signaling and suppressed BMP4-driven smooth muscle activation in models of PAH. BMPER overexpression mitigated the vascular remodeling that characterizes pulmonary arterial ...

Emphysema subtypes, identified via CT, may be linked to cardiopulmonary subphenotypes that can help to target cardiac care in early COPD.

pulmonary arterial hypertension; SLE, systemic lupus erythematosus. Demographic and clinical data were retrospectively collected from patients’ medical records. The following variables were taken into ...